See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
There is no publicly available rating for this medical professional for one of the following reasons:
Adults (18-65), Geriatrics (65+)
English and Italian
Adults (18-65), Geriatrics (65+)
English and Italian
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma. Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally designing combined innovative immunotherapies for relapsing/refractory leukemia and lymphoma. He is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CAR T therapy. His work has been recognized through numerous awards including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), and most recently the 2018 American Society of Hematology Joanne Levy, MD, Memorial Award for Outstanding Achievement. Dr. Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. After completing his fellowship, he was an attending physician in the Hematology and Cell Therapy Division of the Mauriziano Hospital and an Instructor at the Biotechnology School at the University of Torino. From 2012, he was a postdoctoral fellow, and then an instructor at the University of Pennsylvania in the Center for Cellular Immunotherapies where he worked with Drs. June and Gill until appointment to his current position in 2018.
Braendstrup P, Levine B.L., Ruella M.: The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy : 57-69,2020.
Nathan Singh, Yong Lee, Pranali Ravikumar, Olga Shestova, Katharina Hayer, Seok Hong, Xueqing Lu, Raymone Pajarillo, Sangya Agarwal, Shunichiro Kuramitsu, Elena Orlando, Karen Mueller, Charly Good, Shelley L. Berger, Ophir Shalem, Matthew Weitzman, Noelle Frey, Shannon Maude, Stephan Grupp, Carl June, Saar Gill, and Marco Ruella.: Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery : 2020.
Michael Klichinsky, 1, 2, 3, 10 Marco Ruella, 1, 4 Olga Shestova, 1 Andrew Best, 1 Martha Zeeman10, Maggie Schmierer10, Konrad Gabrusciewicz10, Nicholas Anderson10, Nicholas Petty1, Katherine Cummins1, Feng Shen1, Xinhe Shan1, Xueqing Maggie Lu, 1, 5 Kimberly Veliz, 1 Kristin Blouch, 1 Saad Kenderian, 1, 6 Miriam Y. Kim, 1, 7 Roddy O’Connor, 1 Stephen Wallace, 1 Miroslaw Kozlowski, 1 Dylan M. Marchione, 3, 8 Max Shestov, 1 Benjamin A. Garcia, 8 Carl H. June, 1, 3, 9 Saar Gill 1, 3, 4, 11, *.: Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology : 2020.
Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B.: The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.
Front Immunol. 2020 May 12;11:888. doi: 10.3389/fimmu.2020.00888. eCollection 2020. : 2020.
Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. SJ.Haematologica. 2020 May 15:haematol.2019.238675. doi: 10.3324/haematol.2019.238675. Online ahead of print. : 2020.
Marco Ruella, Carl H. June: Beat Pediatric ALL MRD: CD28 CAR-T and Transplant Blood : 2019.
Marco Ruella, David M Barrett, Olga Shestova, Jessica Perazzelli, Avery D Posey, Jr., Seok Jae Hong, Miroslaw Kozlowski, Simon F Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill: A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells Blood : 2019.
1., Singh, Nathan, MD, Frey, Noelle V., Engels, Boris, PhD, Barret, David M., Shestova, Olga, PhD, Ravikumar, Pranali, MS, Shyu, Amy, Highfill, Steven PhD, Zhao, Linlin, Peng, Liaomin, Granda, Brian, Ramones, Melissa, Lu, Xueqing Maggie, Christian, David A, PhD, Perazzelli, Jessica, Lacey, Simon F., PhD, Roy, Nathan, Burkhardt, Janis K., PhD, Colomb, Florent, Abdel-Mohsen, Mohamed, Young, Regina M., PhD, Brogdon, Jennifer, PhD, Grupp, Stephan, MD, PhD, June, Carl H, MD Maude, Shannon L., MD, PhD, Gill, Saar I. MD, PhD and Ruella, Marco, MD: Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy American Society of Hematology Annual Meeting Orlando, Florida (247): 2019.
Nasta, Sunita Dwivedy, MD, Namoglu, Esin C., B.S., Hughes, Mitchell E., PharmD, Chong, Elise A., MD, Svoboda, Jakub, MD, Ballard, Hatcher J., BS, Landsburg, Daniel J., MD, LaRose, Meredith I, MD, Barta, Stefan K., MD, MRCP, MS, Gerson, James N., MD, Ruella, Marco, MD, Frey, Noelle V., MD, Schuster, Stephen J., MD and Porter, David L., MD: Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience American Society of Hematology Annual Meeting Orlando, Florida (3240): 2019.
Wang, Meng, BS, Pruteanu, Iulian, PhD, Cohen, Adam D., MD, Garfall, Alfred L, MD, Milone, Michael C., Tian, Lifeng, PhD, Gonzalez, Vanessa E., Gill, Saar, MD, MRCP, FRCPath, Frey, Noelle V., MD, Barrett, David M., Ruella, Marco, MD, Lacey, Simon F, PhD, Svoboda, Jakub MD, Chong, Elise A. MD, Fraietta, Joseph A, PhD, Davis, Megan, PhD, Nasta, Sunita D, MD, Levine, Bruce L, PhD, Siegel, Don L., MD, PhD, Maude, Shannon L., MD, PhD, Schuster, Stephen J., MD, Stadtmauer, Edward A., MD, FACP, Grupp, Stephan, MD, PhD, Porter, David L., MD, June, Carl H MD and Melenhorst, J. Joseph PhD: Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors American Society of Hematology Annual Meeting Orlando, Florida (622): 2019.
South Tower 8-112 Perelman Center for Advanced Medicine3400 Civic Center Blvd